Back to News
Market Impact: 0.4
Lilly's Foundayo Shows Cardiovascular Safety, Sustained A1C And Weight Benefits In ACHIEVE-4
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Eli Lilly reported Phase 3 ACHIEVE-4 results showing that Foundayo (orforglipron) met cardiovascular-safety expectations while sustaining improvements in blood sugar control, body weight and other cardiometabolic measures. The positive late-stage data support the clinical profile and potential commercialization of Lilly's oral obesity and diabetes treatment candidate.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
LLY0.78
More News
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk
- Stifel cuts Foghorn Therapeutics stock price target on pipeline shift
- Trump Medicare drug pricing model may apply to only four companies after exemptions
- There’s one pharma-linked stock most investors have never heard of. It’s on Josh Brown’s list
- Aktis Oncology initiates phase 1b trial for lung cancer drug
- Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities